鼻窦腺癌手术切除后辅助放疗与生存的关系
本研究利用2004-2016年美国国家癌症数据库,回顾性分析349例手术切除的淋巴结阴性鼻窦腺癌患者,其中154例(44.1%)接受辅助放疗。Kaplan-Meier分析显示辅助放疗组与单纯手术组的5年总生存率无显著差异(65.7% vs 72.6%,p=0.378);仅在临床AJCC T4期患者中,辅助放疗显示出统计学显著的生存获益(56.9% vs 29.9%,p=0.009)。结论认为辅助放疗对切除的鼻窦腺癌似乎不提供显著生存获益,但T4期患者除外。
要点
- 349例淋巴结阴性鼻窦腺癌手术患者中,154例(44.1%)接受辅助放疗。
- 辅助放疗组与单纯手术组5年总生存率无显著差异(65.7% vs 72.6%,p=0.378)。
- 仅临床AJCC T4期患者辅助放疗有显著生存获益(56.9% vs 29.9%,p=0.009)。
核心结论
- 辅助放疗对手术切除的淋巴结阴性鼻窦腺癌患者似乎不提供显著生存获益,但临床AJCC T4期患者除外。
研究设计与样本
- 回顾性数据库研究,使用2004-2016年美国国家癌症数据库(NCDB)提取手术切除的淋巴结阴性鼻窦腺癌患者349例。
主要发现
- 349例患者中154例(44.1%)接受辅助放疗;接受放疗者疾病更晚期且切缘阳性更常见。
- 辅助放疗组与单纯手术组5年总生存率无显著差异(65.7% vs 72.6%,p=0.378)。
- 切缘阳性患者中,辅助放疗组与单纯手术组5年总生存率仍无显著差异(73.8% vs 61.6%,p=0.101)。
- 临床AJCC T4期患者中,辅助放疗组5年总生存率显著高于单纯手术组(56.9% vs 29.9%,p=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to investigate the utility of adjuvant radiation in patients who undergo surgical resection for the management of node-negative sinonasal adenocarcinoma (SNAC). STUDY DESIGN: Retrospective database review. METHODS: The 2004-2016 National Cancer Data Base (NCDB) was used to extract patients with surgically resected node-negative SNAC. Kaplan-Meier survival analysis and Cox-Proportional Hazards Modelling were used to analyze the impact of adjuvant radiation on overall survival (OS) following surgery. RESULTS: 349 patients with SNAC underwent surgical resection. Of these patients, 154 (44.1%) received adjuvant radiotherapy (RT). Although there was no significant difference in race, age, or sex of those receiving RT, those receiving RT have more advanced diseases and are more likely to have positive margins. Kaplan Meier analysis showed no significant difference in 5-year OS in patient who received adjuvant RT in comparison to those who underwent surgical resection alone (65.7% vs. 72.6%, respectively; p = 0.378). In addition, when looking at only patients with positive margins, 5-year OS still did not have a significant difference (73.8% vs. 61.6%, respectively; p = 0.101). Only patients with clinical AJCC T4 showed a statistically significant survival benefit with adjuvant RT (56.9% vs. 29.9%, respectively; p = 0.009). CONCLUSIONS: Adjuvant RT does not appear to provide a significant survival benefit in patients with resected SNAC, with the exception of those with clinically AJCC T4 disease. LEVEL OF EVIDENCE: 4 Laryngoscope, 133:2603-2612, 2023.
引用
- Vedula S, Kheir L, Hu P, et al. Adjuvant Radiation and Survival Following Surgical Resection of Sinonasal Adenocarcinoma. Laryngoscope. 2023. PMID: 36744881. doi:10.1002/lary.30567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。